[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021009475A - Composiciones farmaceuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. - Google Patents

Composiciones farmaceuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.

Info

Publication number
MX2021009475A
MX2021009475A MX2021009475A MX2021009475A MX2021009475A MX 2021009475 A MX2021009475 A MX 2021009475A MX 2021009475 A MX2021009475 A MX 2021009475A MX 2021009475 A MX2021009475 A MX 2021009475A MX 2021009475 A MX2021009475 A MX 2021009475A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
component
giycopyrrolate
hfa
difluoroethane
Prior art date
Application number
MX2021009475A
Other languages
English (en)
Inventor
Timothy James Noakes
Stuart Corr
Original Assignee
Mexichem Fluor Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59997386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021009475(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB1615917.0A external-priority patent/GB2558191A/en
Priority claimed from GBGB1620519.7A external-priority patent/GB201620519D0/en
Application filed by Mexichem Fluor Sa De Cv filed Critical Mexichem Fluor Sa De Cv
Publication of MX2021009475A publication Critical patent/MX2021009475A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica que comprende: (i) un componente de fármaco que comprende una sal farmacéuticamente aceptable de glicopirrolato y un agonista beta 2 de acción prolongada (LABA) seleccionado de formoterol y sales farmacéuticamente aceptables del mismo; y (ii) un componente propulsor que comprende 1,1-difluoroetano (HFA-152a). f es bromuro de glicopirronio y un agonista beta 2 de acción prolongada (LABA) preferido es formoterol fumarato dihidrato. Adicionalmente, la presente invención también se relaciona con un método para mejorar la estabilidad de una composición farmacéutica que comprende un componente propulsor y un componente de fármaco que comprende al menos una sal farmacéuticamente aceptable de glicopirrolato, dicho método comprende usar un componente propulsor que comprende 1,1-difluoroetano (HFA-152a).
MX2021009475A 2016-09-19 2019-03-15 Composiciones farmaceuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. MX2021009475A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1615917.0A GB2558191A (en) 2016-09-19 2016-09-19 Pharmaceutical composition
GBGB1620519.7A GB201620519D0 (en) 2016-12-02 2016-12-02 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2021009475A true MX2021009475A (es) 2021-09-08

Family

ID=59997386

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2021009476A MX392213B (es) 2016-09-19 2017-09-18 Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
MX2019003098A MX387723B (es) 2016-09-19 2017-09-18 Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano.
MX2021009475A MX2021009475A (es) 2016-09-19 2019-03-15 Composiciones farmaceuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2021009476A MX392213B (es) 2016-09-19 2017-09-18 Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
MX2019003098A MX387723B (es) 2016-09-19 2017-09-18 Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano.

Country Status (19)

Country Link
US (9) US10888546B2 (es)
EP (4) EP3915555B1 (es)
JP (3) JP6781829B2 (es)
KR (2) KR20210089273A (es)
CN (4) CN114712338A (es)
AU (3) AU2017328907B2 (es)
CA (1) CA3037092C (es)
CO (1) CO2019002556A2 (es)
ES (4) ES2968212T3 (es)
GE (1) GEP20217239B (es)
IL (1) IL265360B2 (es)
MX (3) MX392213B (es)
MY (1) MY202069A (es)
PE (1) PE20191043A1 (es)
PH (1) PH12019500579B1 (es)
SA (1) SA519401336B1 (es)
UA (1) UA123919C2 (es)
WO (1) WO2018051130A1 (es)
ZA (1) ZA201902053B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
ES2891579T3 (es) * 2016-09-19 2022-01-28 Mexichem Fluor Sa De Cv Composición farmacéutica
WO2018051132A1 (en) * 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
AU2017328910B2 (en) * 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
PH12019500579B1 (en) * 2016-09-19 2024-02-21 Mexichem Fluor Sa De Cv Pharmaceutical composition
US20190388436A1 (en) * 2016-09-19 2019-12-26 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
KR102041239B1 (ko) * 2017-02-22 2019-11-06 도레이첨단소재 주식회사 이형필름
WO2019104191A1 (en) * 2017-11-21 2019-05-31 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3801479A1 (en) * 2018-06-07 2021-04-14 Kindeva Drug Delivery L.P. Fluticasone and vilanterol formulation and inhaler
GB2584686A (en) * 2019-06-11 2020-12-16 Mexichem Fluor Sa De Cv Methods
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
GB2586477A (en) * 2019-08-20 2021-02-24 Mexichem Fluor Sa De Cv Composition and method
KR20220133193A (ko) 2020-01-28 2022-10-04 키에시 파르마슈티시 엣스. 피. 에이. 완충된 약제학적 제제를 포함하는 가압 정량 흡입기
GB2593970B (en) * 2020-02-20 2024-09-04 Chiesi Farm Spa Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
CN111624292A (zh) * 2020-07-10 2020-09-04 武汉伯瑞恒医药科技有限公司 一种测定血清中茚达特罗格隆溴铵浓度的方法
CN112051346A (zh) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 一种同时测定茚达特罗和格隆溴铵含量的hplc方法
MX2024002497A (es) * 2021-09-08 2024-03-15 Kindeva Drug Delivery Lp Inhaladores de dosis medida y composiciones en solucion.
WO2024181972A1 (en) * 2022-03-01 2024-09-06 Kindeva Drug Delivery L.P. Metered dose inhalers and high-dose suspensions

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
GB9024366D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
FR2718437B1 (fr) * 1994-04-11 1996-06-28 Solvay Procédé de séparation du 1,1-difluoroéthane de ses mélanges avec le fluorure d'hydrogène.
DE69530325T2 (de) 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
JP2003525842A (ja) 1997-09-29 2003-09-02 インヘール セラピューティック システムズ， インコーポレイテッド 計量吸入器における使用のための安定化調製物
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ES2234266T3 (es) 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
JP4672143B2 (ja) 1998-08-04 2011-04-20 ヤゴテック アーゲー 医薬用エーロゾル製剤
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
US20030032632A1 (en) 1999-12-24 2003-02-13 Crispps Leslie Alan Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
CN1216600C (zh) 2002-04-24 2005-08-31 信谊药厂 盐酸左旋沙丁胺醇气雾剂及制备工艺
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
EP2319583A1 (en) 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, budesonide and ipratropium
EP1575588A1 (en) 2002-12-16 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Tiotropium containing hfc solution formulations
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
RU2440813C2 (ru) 2004-02-06 2012-01-27 Меда Фарма Гмбх Унд Ко.Кг Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
WO2006004646A1 (en) 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
ES2259915B1 (es) 2005-03-15 2007-12-16 Laboratorio Aldo-Union, S.A. Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion.
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
HRP20161101T1 (hr) 2009-05-29 2016-11-04 Pearl Therapeutics, Inc. PRIPRAVCI ZA PLUĆNI UNOS DUGODJELUJUĆIH MUSKARINSKIH ANTAGONISTA I DUGODJELUJUĆIH ANTAGONISTA β2 ADRENERGIČKOG RECEPTORA, TE PRATEĆI POSTUPCI I SUSTAVI
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR101747474B1 (ko) * 2009-12-23 2017-06-14 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
PH12012501066A1 (en) 2009-12-23 2016-03-02 Chiesi Farm Spa Combination therapy for copd
EP2749277A3 (en) * 2011-02-17 2014-08-27 Cipla Limited Combination of glycopyrronium and vilanterol
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
AU2013336492A1 (en) * 2012-10-23 2015-04-09 Cipla Limited Pharmaceutical composition comprising tiotropium and a hydrofluoroalkane
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
US20150150787A1 (en) 2013-05-22 2015-06-04 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
CN105848642A (zh) 2013-12-30 2016-08-10 奇斯药制品公司 格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物
CN105848641B (zh) 2013-12-30 2021-07-09 奇斯药制品公司 格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物
CA3007050C (en) 2015-12-04 2020-12-08 Mexichem Fluor S.A. De C.V. Pharmaceutical composition comprising a formoterol compound
AU2017328910B2 (en) * 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
PH12019500579B1 (en) * 2016-09-19 2024-02-21 Mexichem Fluor Sa De Cv Pharmaceutical composition

Also Published As

Publication number Publication date
JP2022065106A (ja) 2022-04-26
SA519401336B1 (ar) 2024-05-30
CO2019002556A2 (es) 2020-02-18
MY202069A (en) 2024-03-31
ES2957459T3 (es) 2024-01-19
EP3915555A1 (en) 2021-12-01
US20210322378A1 (en) 2021-10-21
US11690823B2 (en) 2023-07-04
US11826348B2 (en) 2023-11-28
CN114515284A (zh) 2022-05-20
KR20210089273A (ko) 2021-07-15
PH12019500579B1 (en) 2024-02-21
IL265360B2 (en) 2023-02-01
AU2021205045C1 (en) 2022-12-22
ZA201902053B (en) 2024-10-30
US20210322377A1 (en) 2021-10-21
EP3915555B1 (en) 2023-06-28
US20190255018A1 (en) 2019-08-22
AU2017328907A1 (en) 2019-04-04
EP3515432B1 (en) 2021-08-25
IL265360B (en) 2022-10-01
BR112019005133A2 (pt) 2019-06-04
US10888546B2 (en) 2021-01-12
IL265360A (en) 2019-05-30
US20200016120A1 (en) 2020-01-16
US11103480B2 (en) 2021-08-31
AU2017328907B2 (en) 2020-04-09
JP6781829B2 (ja) 2020-11-04
ES2968212T3 (es) 2024-05-08
ES2892673T3 (es) 2022-02-04
KR20190063467A (ko) 2019-06-07
JP7041703B2 (ja) 2022-03-24
KR102277635B1 (ko) 2021-07-19
CN109789126B (zh) 2022-08-05
JP2020114826A (ja) 2020-07-30
ES2968453T3 (es) 2024-05-09
MX2021009476A (es) 2022-05-11
CA3037092C (en) 2022-06-21
MX392213B (es) 2025-03-21
US20240050405A1 (en) 2024-02-15
AU2020202626A1 (en) 2020-05-14
EP3607936A1 (en) 2020-02-12
MX387723B (es) 2025-03-18
US20240050404A1 (en) 2024-02-15
CA3037092A1 (en) 2018-03-22
WO2018051130A1 (en) 2018-03-22
PH12019500579A1 (en) 2019-08-19
EP3515432A1 (en) 2019-07-31
US11642330B2 (en) 2023-05-09
UA123919C2 (uk) 2021-06-23
US20210401800A1 (en) 2021-12-30
US11179366B2 (en) 2021-11-23
EP3610871A1 (en) 2020-02-19
AU2020202626B2 (en) 2021-08-05
JP7228726B2 (ja) 2023-02-24
AU2021205045A1 (en) 2021-08-12
US20200016119A1 (en) 2020-01-16
PE20191043A1 (es) 2019-08-06
US11826349B2 (en) 2023-11-28
MX2019003098A (es) 2019-08-01
GEP20217239B (en) 2021-03-25
CN114712338A (zh) 2022-07-08
JP2019529428A (ja) 2019-10-17
EP3607936B1 (en) 2023-11-08
US20210322379A1 (en) 2021-10-21
EP3610871B1 (en) 2023-11-08
AU2021205045B2 (en) 2022-08-25
CN114272238A (zh) 2022-04-05
CN109789126A (zh) 2019-05-21
NZ752430A (en) 2021-02-26

Similar Documents

Publication Publication Date Title
ZA201902053B (en) Pharmaceutical composition
ZA201902051B (en) Pharmaceutical composition
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
ZA201902049B (en) Pharmaceutical composition
MX2021010022A (es) Composicion farmaceutica.
PH12020500446A1 (en) Bisamide sarcomere activating compounds and uses thereof
ZA201902052B (en) Pharmaceutical composition
ZA202006535B (en) Pharmaceutical composition comprising salbutamol
PH12016502246B1 (en) Carboxamide derivatives
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
NZ762402A (en) Pharmaceutical formulations for adalimumab
EA201990506A1 (ru) Фармацевтическая композиция
IL284132A (en) A pharmaceutical compound, a method for its preparation and its use as a medicinal substance
PH12016502527B1 (en) Stabilized desmopressin